Reduction of selling, general and administrative expenses
First written in FY2017-Q1. 7 of 35 entries say "Advanced", first in FY2024-Q1. Latest entry: FY2026.
- FY2026AdvancedAnnual report
「The effects of the business restructuring and structural reforms pursued more vigorously than in the previous fiscal year became clearly evident, bringing the figure to ¥1,382 million, down 8.0% from the previous fiscal year, while operating income was ¥201 million, compared with an operating loss of ¥121 million in the previous fiscal year, marking a return to profitability for the first time in 4 periods,」
Business restructuring, structural reforms and cost-control initiatives reduced selling, general and administrative expenses to ¥1,382 million, down 8.0% from the previous fiscal year, contributing to a return to operating profitability. - FY2025AdvancedAnnual report
「Fundamental business restructuring, including the dissolution of overseas consolidated subsidiaries and joint ventures, together with various cost-control initiatives, brought selling, general and administrative expenses to ¥1,502 million, down 21.2% year on year.」
Business restructuring and cost-control initiatives reduced selling, general and administrative expenses by 21.2% from the previous fiscal year. R&D expenses also declined to ¥128 million, down 40.3% from the previous fiscal year. - FY2025-H1AdvancedAnnual report
「On the cost side, implementing fundamental business restructuring and various cost-control initiatives brought selling, general and administrative expenses to ¥758 million, down 20.6% year on year.」
Fundamental business restructuring and cost-control initiatives brought selling, general and administrative expenses to ¥758 million, down 20.6% year on year. R&D expenses also declined to ¥51 million, down 52.2% year on year. - FY2024AdvancedAnnual report
「On the cost side, employees worked together during the second half to implement major reductions in selling and administrative expenses, bringing selling, general and administrative expenses to ¥1,906 million, down 22.6% year on year.」
The second-half plan to reduce selling and administrative expenses was implemented, bringing selling, general and administrative expenses to ¥1,906 million, down 22.6% year on year. R&D expenses also declined to ¥216 million, down 42.4%. - FY2024-Q3AdvancedAnnual report
「R&D expenses declined to ¥171 million, down 39.1% year on year, partly because product application development costs had run their course, while lower personnel expenses and other factors brought selling, general and administrative expenses to ¥1,423 million, down 22.7% year on year.」
R&D expenses and selling, general and administrative expenses were reduced year on year due to product application development costs running their course, lower personnel expenses and other factors. Implementation of the SG&A expense reduction plan expanded. - FY2024-Q2AdvancedAnnual report
「During the cumulative second quarter of the consolidated fiscal year, all departments worked on plans to reduce SG&A expenses, bringing selling, general and administrative expenses to ¥954 million, down 24.0% year on year.」
Plans to reduce SG&A expenses were implemented across departments, bringing selling, general and administrative expenses to ¥954 million, down 24.0% year on year. - FY2024-Q1AdvancedAnnual report
「On the cost side, implementation of various cost-control initiatives brought selling, general and administrative expenses to ¥504 million, down 22.2% year on year.」
Implementation of cost-control initiatives brought selling, general and administrative expenses to ¥504 million, down 22.2% year on year. R&D expenses also declined to ¥55 million, down 49.0% year on year. - FY2023Continued decline in R&D expenses and increase in SG&A expensesAnnual report
「R&D expenses declined to ¥375 million, down 2.7% from the previous fiscal year, as product application development costs ran their course. However, higher costs related to the Tokyo PCR and Other Testing Free-of-Charge Program and support activities for the company's own products brought selling, general and administrative expenses to ¥2,462 million, up 5.5% from the previous fiscal year.」
R&D expenses declined, while SG&A expenses increased due to the Tokyo PCR and Other Testing Free-of-Charge Program and support costs for the company's own products. - FY2023-Q3Continued decline in R&D expenses and increase in SG&A expensesAnnual report
「On the cost side, R&D expenses declined to ¥281 million, down 21.3% year on year, partly because product application development costs had run their course. However, higher personnel expenses and other factors brought selling, general and administrative expenses to ¥1,841 million, up 4.8% year on year.」
R&D expenses declined to ¥281 million, down 21.3% year on year, as product application development costs ran their course, while selling, general and administrative expenses increased to ¥1,841 million, up 4.8% year on year, due to higher personnel expenses and other factors. - FY2023-Q2Continued decline in R&D expenses and increase in SG&A expensesAnnual report
「R&D expenses declined to ¥179 million, down 23.1% year on year, partly because product application development costs had run their course. However, higher personnel expenses, sales-related expenses and other factors brought selling, general and administrative expenses to ¥1,256 million, up 10.3% year on year.」
R&D expenses declined as product application development costs ran their course, while selling, general and administrative expenses increased due to higher personnel and sales-related expenses. - FY2023-Q1Slight decline in R&D expenses; increase in SG&A expensesAnnual report
「R&D expenses declined to ¥109 million, down 2.0% year on year, partly because product application development costs had run their course. However, higher personnel expenses, sales-related expenses and other factors brought selling, general and administrative expenses to ¥648 million, up 18.6% year on year.」
R&D expenses declined as product application development costs ran their course, while SG&A expenses increased 18.6% year on year due to higher personnel and sales-related expenses. - FY2022Continued decline in R&D expenses and increase in SG&A expensesAnnual report
「R&D expenses declined to ¥385 million, down 30.1% from the previous fiscal year, as product application development costs ran their course. However, higher sales activity costs for own-brand products and higher personnel expenses and other factors brought selling, general and administrative expenses to ¥2,334 million, up 6.0% from the previous fiscal year.」
R&D expenses declined as product application development costs ran their course, while SG&A expenses increased due to sales activity costs for own-brand products, higher personnel expenses and other factors. The composition shifted from the previous cost-reduction trend. - FY2022-Q3Continued decline in R&D expenses and increase in SG&A expensesAnnual report
「On the cost side, R&D expenses declined to ¥358 million, down 24.9% year on year, as product application development costs ran their course. However, higher sales activity costs for own-brand products and higher personnel expenses and other factors brought selling, general and administrative expenses to ¥1,757 million, up 9.7% year on year.」
R&D expenses declined 24.9% year on year as product application development costs ran their course, while selling, general and administrative expenses increased 9.7% due to higher sales activity costs for own-brand products and higher personnel expenses and other factors. - FY2022-Q2R&D expenses declined; SG&A expenses increasedAnnual report
「On the cost side, R&D expenses declined to ¥233 million, down 28.4% year on year, partly because product application development costs had run their course. However, higher costs for sales activities for the company's own products and higher personnel expenses and other factors brought selling, general and administrative expenses to ¥1,138 million, up 7.3% year on year.」
R&D expenses declined 28.4% year on year as product application development costs ran their course, while SG&A expenses increased 7.3% due to higher sales activity costs for the company's own products and higher personnel expenses. - FY2022-Q1R&D expenses declined; SG&A expenses increasedAnnual report
「R&D expenses declined to ¥111 million, down 33.8% year on year, partly because product application development costs had run their course. However, higher personnel expenses and other factors brought selling, general and administrative expenses to ¥546 million, up 4.9% year on year.」
R&D expenses declined as product application development costs ran their course, while selling, general and administrative expenses increased due to higher personnel expenses and other factors. The composition shifted from the previous cost-reduction trend. - FY2021R&D expenses and SG&A expenses increasedAnnual report
「On the cost side, R&D expenses increased to ¥551 million, up 5.7% from the previous fiscal year, partly due to application development costs for the fully automated PCR testing system. As a result, selling, general and administrative expenses rose to ¥2,202 million, up 34.3% from the previous fiscal year.」
Application development costs for the fully automated PCR testing system and other factors increased R&D expenses to ¥551 million and selling, general and administrative expenses to ¥2,202 million. - FY2021-Q3R&D expenses and SG&A expenses increasedAnnual report
「On the cost side, R&D expenses increased to ¥476 million, up 31.1% year on year, partly due to short-term product application development costs. As a result, selling, general and administrative expenses rose to ¥1,601 million, up 35.4% year on year.」
Short-term product application development costs and other factors increased R&D expenses to ¥476 million, up 31.1% year on year, while selling, general and administrative expenses also rose to ¥1,601 million, up 35.4%. - FY2021-Q2R&D expenses and SG&A expenses increasedAnnual report
「On the cost side, R&D expenses increased to ¥326 million, up 40.0% year on year, partly due to short-term product application development costs. As a result, selling, general and administrative expenses rose to ¥1,061 million, up 35.4% year on year.」
Short-term product application development costs and other factors increased R&D expenses to ¥326 million, up 40.0% year on year, while selling, general and administrative expenses also rose to ¥1,061 million, up 35.4%. - FY2021-Q1R&D expenses and SG&A expenses increasedAnnual report
「On the cost side, R&D expenses increased to ¥168 million, up 48.5% year on year, partly due to short-term product application development costs. As a result, selling, general and administrative expenses rose to ¥521 million, up 34.1% year on year.」
Short-term product application development costs and other factors increased R&D expenses to ¥168 million, up 48.5% year on year, while selling, general and administrative expenses also rose to ¥521 million, up 34.1%. - FY2020R&D expenses and SG&A expenses increasedAnnual report
「On the cost side, R&D expenses increased to ¥522 million, up 38.4% from the previous fiscal year, partly due to application development costs for the fully automated PCR testing system. As a result, selling, general and administrative expenses rose to ¥1,639 million, up 18.2% from the previous fiscal year.」
Application development costs for the fully automated PCR testing system and other factors increased R&D expenses to ¥522 million and selling, general and administrative expenses to ¥1,639 million. - FY2020-Q3R&D expenses and SG&A expenses increasedAnnual report
「R&D expenses increased to ¥363 million, up 21.5% year on year, partly due to short-term product application development costs. In addition, higher depreciation resulting from capital investment to reduce the cost of mass-producing reagents and other factors brought selling, general and administrative expenses to ¥1,182 million, up 11.0% year on year.」
R&D expenses and selling, general and administrative expenses both increased year on year due to short-term product application development costs and higher depreciation associated with capital investment to reduce the cost of mass-producing reagents. - FY2020-Q2R&D expenses and SG&A expenses increasedAnnual report
「R&D expenses increased to ¥232 million, up 9.4% year on year, partly due to short-term product application development costs. In addition, higher depreciation resulting from capital investment to reduce the cost of mass-producing reagents and other factors brought selling, general and administrative expenses to ¥784 million, up 9.7% year on year.」
R&D expenses and selling, general and administrative expenses both increased year on year due to short-term product application development costs and higher depreciation associated with capital investment to reduce the cost of mass-producing reagents. - FY2020-Q1R&D expenses and SG&A expenses increasedAnnual report
「R&D expenses increased to ¥113 million, up 10.1% year on year, partly due to short-term product application development costs. In addition, higher depreciation resulting from capital investment to reduce the cost of mass-producing reagents and other factors brought selling, general and administrative expenses to ¥388 million, up 14.7% year on year.」
R&D expenses and selling, general and administrative expenses increased year on year due to short-term product application development costs and higher depreciation associated with capital investment to reduce the cost of mass-producing reagents. - FY2019R&D expenses and SG&A expenses declinedAnnual report
「R&D expenses declined to ¥377 million, down 33.6% from the previous fiscal year. The company also worked to reduce other expenses, bringing selling, general and administrative expenses to ¥1,387 million, down 18.3% from the previous fiscal year.」
Both R&D expenses and selling, general and administrative expenses declined from the previous fiscal year, confirming the results of cost reductions for the full fiscal year. - FY2019-Q3R&D expenses and SG&A expenses declinedAnnual report
「On the cost side, R&D expenses declined to ¥299 million, down 31.0% year on year. The company also worked to reduce other expenses, bringing selling, general and administrative expenses to ¥1,065 million, down 15.5% year on year.」
R&D expenses declined 31.0% year on year and selling, general and administrative expenses declined 15.5%, continuing the reported results of cost reductions. - FY2019-Q2R&D expenses and SG&A expenses declinedAnnual report
「On the cost side, R&D expenses declined to ¥213 million, down 29.0% year on year. The company also worked to reduce other expenses, bringing selling, general and administrative expenses to ¥715 million, down 15.8% year on year.」
R&D expenses declined 29.0% year on year and selling, general and administrative expenses declined 15.8%, continuing the reported results of cost reductions. - FY2019-Q1R&D expenses and SG&A expenses declinedAnnual report
「On the cost side, R&D expenses declined to ¥102 million, down 27.9% year on year. The company also worked to reduce other expenses, bringing selling, general and administrative expenses to ¥338 million, down 17.3% year on year.」
R&D expenses declined 27.9% year on year and selling, general and administrative expenses declined 17.3%, continuing the reported results of cost reductions. - FY2018R&D expenses and SG&A expenses declinedAnnual report
「R&D expenses were ¥568 million, down 12.2% year on year. The company also worked to reduce other expenses, bringing selling, general and administrative expenses to ¥1,697 million, down 5.0% year on year.」
Both R&D expenses and selling, general and administrative expenses declined year on year. - FY2018-Q3R&D expenses and SG&A expenses declinedAnnual report
「On the cost side, R&D expenses declined to ¥433 million, down 9.3% year on year. The company also worked to reduce other expenses, bringing selling, general and administrative expenses to ¥1,260 million, down 6.2% year on year.」
For the cumulative 3 quarters, both R&D expenses and selling, general and administrative expenses declined year on year, and the results of cost reductions were reported. - FY2018-Q2Continued reduction in SG&A expenses; increase in R&D expensesAnnual report
「On the cost side, R&D expenses increased to ¥299 million, up 3.1% year on year, but efforts to reduce other expenses brought selling, general and administrative expenses to ¥848 million, down 3.3% year on year.」
R&D expenses increased 3.1% year on year, while selling, general and administrative expenses declined 3.3% through reductions in other expenses. - FY2018-Q1RestatedAnnual report
「On the cost side, R&D expenses increased to ¥142 million, up 8.0% year on year, but efforts to reduce other expenses brought selling, general and administrative expenses to ¥409 million, down 4.1% year on year.」
Although R&D expenses increased, selling, general and administrative expenses declined 4.1% year on year through reductions in other expenses, indicating that cost-reduction efforts continued. - FY2017RestatedAnnual report
「R&D expenses were ¥647 million, down 16.8% year on year. The company also worked to reduce other expenses, bringing selling, general and administrative expenses to ¥1,786 million, down 16.4% year on year.」
The effort to reduce R&D expenses and selling, general and administrative expenses year on year continued to be reported for the full fiscal year. - FY2017-Q3RestatedAnnual report
「On the cost side, R&D expenses were ¥478 million, down 6.5% year on year. The company also worked to reduce other expenses, bringing selling, general and administrative expenses to ¥1,344 million, down 13.4% year on year.」
The company continued to report efforts to reduce R&D expenses and selling, general and administrative expenses year on year. - FY2017-Q2RestatedAnnual report
「On the cost side, R&D expenses were ¥290 million, down 11.4% year on year. The company also worked to reduce other expenses, bringing selling, general and administrative expenses to ¥877 million, down 16.9% year on year.」
The initiatives and results involving year-on-year reductions in R&D expenses and selling, general and administrative expenses continued to be reported. - FY2017-Q1First statedAnnual report
「On the cost side, R&D expenses declined to ¥132 million, down 15.8% year on year. Efforts to reduce other expenses also helped bring selling, general and administrative expenses to ¥427 million, down 19.3% year on year, representing a significant reduction in expenses.」
The year-on-year declines in R&D expenses and selling, general and administrative expenses during the quarter were described for the first time as a standalone initiative resulting from cost reductions.